III期卵巢癌患者接受腹腔化疗后有多大比例可能治愈?对NRG/GOG腹腔与静脉化疗随机临床试验中长期(≥10年)生存者的分析
分析3项NRG/GOG随机试验中1174例III期上皮性卵巢癌患者,10年总生存率为26%(95%CI 23-28%),无进展生存≥10年者为18%(95%CI 16-20%);多因素Cox分析显示年轻年龄是LTDFS≥10年的唯一独立预后因素。
要点
- III期上皮性卵巢癌患者10年总生存率为26%(95%CI 23-28%)。
- 无进展生存≥10年的患者占18%(95%CI 16-20%),可能为治愈。
- 多因素分析中年轻年龄是LTDFS≥10年的唯一独立预后因素。
核心结论
- 约18%的III期上皮性卵巢癌患者无进展生存≥10年,位于生存曲线末端,可能已治愈。
- 结果为评估PARP抑制剂一线维持试验对生存结局的影响提供了比较基准。
研究设计与样本
- 分析3项成熟的NRG/GOG随机临床试验(104、114、172)的数据。
- 共纳入1174例随机化患者,收集人口学、临床病理资料、给药途径和生存结局。
- 采用Kaplan-Meier法评估生存≥10年患者,Cox回归分析评估LTDFS的独立预后因素。
主要发现
- 1174例随机化患者中,10年总生存率为26%(95%CI 23-28%)。
- 无进展生存≥10年(LTDFS≥10年)者为18%(95%CI 16-20%)。
- LTDFS≥10年患者的中位年龄为54.6岁(p < 0.001)。
- 多因素Cox分析显示,年轻年龄(p < 0.001)是LTDFS≥10年的唯一独立预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS. METHODS: Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS. RESULTS: Of 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23-28%) and LTDFS ≥10 years was 18% (95% CI, 16-20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis. CONCLUSIONS: Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.
引用
- Pitiyarachchi O, Friedlander M, Java JJ, et al. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecol Oncol. 2022. PMID: 35835612. doi:10.1016/j.ygyno.2022.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。